Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02739373 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT02739373 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 76 participants.
The verdict
NCT02739373, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
The main purpose of this study is to measure the amount of study drug (BMS-986189) in the blood and urine and to see if BMS-986189 is safe and well-tolerated in healthy people after a single dose.
Interventions
- OTHER Placebo
- DRUG BMS-986189
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2016-04-18 |
| Est. Completion | 2016-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02739373
The ClinicalTrials.gov registry entry for NCT02739373 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02739373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02739373 about?
NCT02739373 is a clinical study titled "Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects". The main purpose of this study is to measure the amount of study drug (BMS-986189) in the blood and urine and to see if BMS-986189 is safe and well-tolerated in healthy people after a single dose.
What is the current status of trial NCT02739373?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2016-04-18. Estimated completion is 2016-12-14.
What interventions are being tested in trial NCT02739373?
The interventions under investigation include: Placebo (OTHER), BMS-986189 (DRUG).
Who is sponsoring clinical trial NCT02739373?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.